Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion ...

Orchestra BioMed enrols first patients in Virtue SAB pivotal investigational device exemption coronary trial: New Hope, Pennsylvania Wednesday, October 29, 2025, 18:00 Hrs [IST] O ...

Orchestra BioMed Holdings ( ($OBIO) ) just unveiled an update. On October 28, 2025, Orchestra BioMed Holdings announced a new strategic agreement ...

New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a ...

After vocal cord surgery, many patients develop stiff vocal folds that impact their ability to speak. Hydrogels can help ...

From ingestible pills that track gut health to smart bandages that can autonomously provide required treatment to wounds, ...

Lifecore Biomedical ( ($LFCR) ) has shared an update. On October 29, 2025, Lifecore Biomedical held its annual meeting of stockholders, where ...

Orchestra BioMed (Nasdaq:OBIO) announced today that it entered into a termination and right of first refusal agreement with ...

The rapid advancement of sensing and artificial intelligence (AI) systems has paved the way for the introduction of ...

This advancement is detailed in the journal Device and written by a team led by biomedical engineer Jung Seung Lee at ...

Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to ...

Inspired by the world’s largest land animal, researchers have created and tested what they say is the world’s smallest 3D ...